找回密碼
 To register

QQ登錄

只需一步,快速開(kāi)始

掃一掃,訪問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: Radiation Oncology Study Guide; Ravi A. Chandra,Celine B. Ord,Charles R. Thomas Jr Textbook 2021Latest edition Springer Nature Switzerland

[復(fù)制鏈接]
樓主: 不讓做的事
21#
發(fā)表于 2025-3-25 03:25:17 | 只看該作者
Skin Cancer and Uveal Melanoma,in clinical staging per the American Joint Committee on Cancer and novel therapeutic agents. Given the rarity of uveal melanoma, this disease entity is briefly included in the same chapter as cutaneous melanoma as radiation is an integral component of management organ preservation.
22#
發(fā)表于 2025-3-25 11:12:48 | 只看該作者
Head and Neck Cancer,clude updates in clinical staging as introduced by the American Joint Committee on Cancer, management of HPV-positive oropharynx cancer, approaches to cervical node management, and new information on systemic regimens in the setting of concurrent or sequential chemoradiation.
23#
發(fā)表于 2025-3-25 12:38:35 | 只看該作者
Thoracic Cancer,herapy, and advancements in concurrent chemoradiation. This section has also been expanded to incorporate major studies in NSCLC highlighting dose escalation and the use of adjuvant immunotherapy. Also, this section includes role of consolidative radiation and prophylactic cranial radiation in SCLC.
24#
發(fā)表于 2025-3-25 19:43:43 | 只看該作者
25#
發(fā)表于 2025-3-25 21:25:17 | 只看該作者
26#
發(fā)表于 2025-3-26 00:31:20 | 只看該作者
27#
發(fā)表于 2025-3-26 08:06:18 | 只看該作者
28#
發(fā)表于 2025-3-26 08:55:03 | 只看該作者
Breast Cancer, mitigate toxicity. Additionally, molecular testing has opened up avenues for successful targeted agents and reassessment in radiation therapy strategies. This section has been expanded to incorporate the aforementioned evolution of breast radiotherapy.
29#
發(fā)表于 2025-3-26 13:13:03 | 只看該作者
30#
發(fā)表于 2025-3-26 19:10:38 | 只看該作者
Pediatric Non-CNS Tumors,kemia, lymphoma, neuroblastoma, Wilms’ tumor, Ewing sarcoma, rhabdomyosarcoma, and retinoblastoma. Similar to pediatric CNS tumors, treatment strategies for pediatric body tumors continue to evolve as we learn more about molecular markers and targeted novel therapies.
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-25 11:44
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
石河子市| 同心县| 泽库县| 徐闻县| 鄂尔多斯市| 太和县| 汉寿县| 千阳县| 永福县| 吴江市| 榆林市| 襄樊市| 林甸县| 凤翔县| 虎林市| 清丰县| 南宫市| 绵阳市| 太和县| 炉霍县| 苍南县| 苍梧县| 绍兴市| 凭祥市| 九江市| 阿克苏市| 如皋市| 蒲江县| 元氏县| 万源市| 阿拉善右旗| 微博| 余江县| 拉萨市| 洮南市| 沙湾县| 吉木萨尔县| 崇信县| 双城市| 凌云县| 海晏县|